Now Reading: Wockhardt gets USFDA nod for novel drug Zaynich
-
01
Wockhardt gets USFDA nod for novel drug Zaynich
Wockhardt has received US Food and Drug Administration approval for Zaynich, a novel drug discovered and developed in-house, marking a first for an Indian pharmaceutical company. The company spent nearly Rs 6,800…
The Story in Brief
Wockhardt has received US Food and Drug Administration approval for Zaynich, a novel drug discovered and developed in-house, marking a first for an Indian pharmaceutical company. The company spent nearly Rs 6,800 crore and over two decades on the drug’s development. Zaynich is expected to drive Wockhardt’s next phase of growth after it returned to profitability in FY26.
The approval comes as India Inc reports stronger profit margins but moderate revenue growth, with business confidence hitting a record low in the June quarter, according to the BT-C Fore Business Confidence Index. The survey cited global uncertainties and domestic headwinds as factors weighing on sentiment.
The Indian Opinion
The cheer around Wockhardt’s USFDA approval for Zaynich is understandable, but investors should temper euphoria with realism. A single drug, even a novel one, does not instantly transform a company that has burned Rs 6,800 crore over two decades. The narrative of Indian pharma “leapfrogging” into global innovation is seductive, but this is one data point, not a trend. The real test will be in commercial execution: Can Wockhardt manufacture at scale, secure pricing, and win prescriptions against entrenched competitors? The next four quarters will reveal whether this is a genuine breakthrough or another false dawn.
Source: businesstoday.in
This story was synthesised by AI from the source linked above.
